HC Wainwright set a $55.00 target price on Pacira Pharmaceuticals (NASDAQ:PCRX) in a report released on Thursday, January 4th. The brokerage currently has a buy rating on the stock.

PCRX has been the topic of a number of other research reports. Zacks Investment Research lowered Pacira Pharmaceuticals from a buy rating to a hold rating in a report on Monday, October 9th. Canaccord Genuity reiterated a buy rating and set a $44.00 price target (down from $48.00) on shares of Pacira Pharmaceuticals in a report on Sunday, October 1st. CIBC assumed coverage on Pacira Pharmaceuticals in a report on Thursday, September 7th. They set a market perform rating on the stock. Wedbush reiterated an outperform rating and set a $87.00 price target on shares of Pacira Pharmaceuticals in a report on Wednesday, October 25th. Finally, Needham & Company LLC reiterated a buy rating on shares of Pacira Pharmaceuticals in a report on Tuesday, September 26th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the stock. Pacira Pharmaceuticals presently has an average rating of Hold and a consensus target price of $49.06.

How to Become a New Pot Stock Millionaire

Pacira Pharmaceuticals (NASDAQ:PCRX) opened at $38.05 on Thursday. Pacira Pharmaceuticals has a fifty-two week low of $29.81 and a fifty-two week high of $58.95. The company has a debt-to-equity ratio of 1.03, a quick ratio of 6.24 and a current ratio of 6.99.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The company had revenue of $67.30 million for the quarter, compared to analyst estimates of $68.99 million. During the same quarter last year, the company earned $0.20 earnings per share. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. sell-side analysts predict that Pacira Pharmaceuticals will post -0.85 EPS for the current year.

In other Pacira Pharmaceuticals news, Director Mark A. Kronenfeld bought 1,000 shares of Pacira Pharmaceuticals stock in a transaction that occurred on Friday, November 10th. The stock was acquired at an average cost of $41.60 per share, for a total transaction of $41,600.00. Following the completion of the transaction, the director now directly owns 6,795 shares in the company, valued at $282,672. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO David M. Stack sold 58,885 shares of the business’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $38.34, for a total value of $2,257,650.90. Following the transaction, the chief executive officer now owns 159,164 shares of the company’s stock, valued at $6,102,347.76. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 98,960 shares of company stock valued at $3,868,341. 6.60% of the stock is owned by company insiders.

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. lifted its stake in Pacira Pharmaceuticals by 9.2% during the second quarter. BlackRock Inc. now owns 3,478,281 shares of the company’s stock worth $165,914,000 after purchasing an additional 294,494 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Pacira Pharmaceuticals by 7.4% in the 2nd quarter. Vanguard Group Inc. now owns 3,072,074 shares of the company’s stock valued at $146,538,000 after acquiring an additional 211,982 shares during the last quarter. HealthCor Management L.P. lifted its stake in shares of Pacira Pharmaceuticals by 63.1% in the 2nd quarter. HealthCor Management L.P. now owns 1,793,799 shares of the company’s stock valued at $85,564,000 after acquiring an additional 693,799 shares during the last quarter. Westfield Capital Management Co. LP lifted its stake in shares of Pacira Pharmaceuticals by 5.3% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,285,850 shares of the company’s stock valued at $48,284,000 after acquiring an additional 64,510 shares during the last quarter. Finally, Macquarie Group Ltd. lifted its stake in shares of Pacira Pharmaceuticals by 5.8% in the 3rd quarter. Macquarie Group Ltd. now owns 1,154,545 shares of the company’s stock valued at $43,353,000 after acquiring an additional 63,015 shares during the last quarter.

ILLEGAL ACTIVITY NOTICE: “Pacira Pharmaceuticals (PCRX) Given a $55.00 Price Target at HC Wainwright” was originally published by Marea Informative and is the sole property of of Marea Informative. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.mareainformativa.com/2018/01/30/hc-wainwright-analysts-give-pacira-pharmaceuticals-pcrx-a-55-00-price-target-updated-updated-updated.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.